高血圧治療薬市場：治療法、分析、タイプ、流通別-2023～2030年の世界予測

高血圧治療薬の世界市場は、2023年にCAGR 8.71%で268億8,000万米ドル、2030年には483億2,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の高血圧治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.高血圧治療薬の世界市場規模および予測は？

2.予測期間中、世界の高血圧治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.高血圧治療薬の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.高血圧治療薬の世界市場における競争戦略は？

5.高血圧治療薬の世界市場における技術動向と規制の枠組みは？

6.高血圧治療薬の世界市場における主要ベンダーの市場シェアは？

7.高血圧治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高血圧に伴う合併症に関する意識の高まり
    • 高齢者人口に伴う高血圧症の有病率の増加
    • 高血圧の薬物治療の進歩
  • 抑制要因
    • 遠隔地では高血圧治療薬が入手できない
  • 機会
    • 民間および政府機関による研究開発への取り組みの拡大
    • 新薬開発への一層の注力
  • 課題
    • 治療選択肢の副作用に対する懸念の増大
    • 代替ジェネリック医薬品の増加
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 高血圧治療薬市場：治療法別

• イントロダクション
• アルファブロッカー
• アンジオテンシン変換酵素阻害剤
• アンジオテンシン受容体遮断薬
• ベータ遮断薬血管拡張薬
• カルシウムチャネルブロッカー
• 利尿薬
• レニン阻害剤

第7章 高血圧治療薬市場：分析別

• イントロダクション
• 肺高血圧症治療薬
• 全身性高血圧症治療薬

第8章 高血圧治療薬市場：タイプ別

• イントロダクション
• 併用療法
• 単一療法

第9章 高血圧治療薬市場：流通別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの高血圧治療薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の高血圧治療薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの高血圧治療薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. HYPERTENSION DRUG MARKET RESEARCH PROCESS
• FIGURE 2. HYPERTENSION DRUG MARKET SIZE, 2022 VS 2030
• FIGURE 3. HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
• FIGURE 5. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2022 VS 2030 (%)
• FIGURE 6. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 7. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
• FIGURE 8. HYPERTENSION DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. HYPERTENSION DRUG MARKET DYNAMICS
• FIGURE 10. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. HYPERTENSION DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 5. HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 13. HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16. HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 19. HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. CANADA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. CHINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. CHINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 61. INDIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 62. INDIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 130. ITALY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. ITALY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 146. POLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. POLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 150. QATAR HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. QATAR HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 190. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 191. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 192. HYPERTENSION DRUG MARKET LICENSE & PRICING

The Global Hypertension Drug Market is forecasted to grow significantly, with a projected USD 26.88 billion in 2023 at a CAGR of 8.71% and expected to reach a staggering USD 48.32 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Hypertension Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Hypertension Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Therapy, market is studied across Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta Blockers Vasodilators, Calcium Channel Blockers, Diuretics, and Renin Inhibitors. The Angiotensin Receptor Blockers is projected to witness significant market share during forecast period.

Based on Analysis, market is studied across Pulmonary Hypertension Drugs and Systemic Hypertension Drugs. The Pulmonary Hypertension Drugs is projected to witness significant market share during forecast period.

Based on Type, market is studied across Combination Therapy and Mono Therapy. The Combination Therapy is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Hypertension Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Hypertension Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hypertension Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hypertension Drug Market?

4. What is the competitive strategic window for opportunities in the Global Hypertension Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Hypertension Drug Market?

6. What is the market share of the leading vendors in the Global Hypertension Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Hypertension Drug Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Hypertension Drug Market, by Therapy, 2022 vs 2030
• 4.3. Hypertension Drug Market, by Analysis, 2022 vs 2030
• 4.4. Hypertension Drug Market, by Type, 2022 vs 2030
• 4.5. Hypertension Drug Market, by Distribution, 2022 vs 2030
• 4.6. Hypertension Drug Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in awareness related to complications associated with hypertension
    • 5.1.1.2. Increasing prevalence of hypertension coupled with geriatric population
    • 5.1.1.3. Advances in pharmacologic treatment of hypertension
  • 5.1.2. Restraints
    • 5.1.2.1. Unavailability of hypertension drugs in remote areas
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing initiatives by private and government organizations for R&D
    • 5.1.3.2. Increasing focus on development of new drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Increased concern of side-effects of treatment options
    • 5.1.4.2. Rising number of alternate generic drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Hypertension Drug Market, by Therapy

• 6.1. Introduction
• 6.2. Alpha Blockers
• 6.3. Angiotensin Converting Enzyme Inhibitor
• 6.4. Angiotensin Receptor Blockers
• 6.5. Beta Blockers Vasodilators
• 6.6. Calcium Channel Blockers
• 6.7. Diuretics
• 6.8. Renin Inhibitors

7. Hypertension Drug Market, by Analysis

• 7.1. Introduction
• 7.2. Pulmonary Hypertension Drugs
• 7.3. Systemic Hypertension Drugs

8. Hypertension Drug Market, by Type

• 8.1. Introduction
• 8.2. Combination Therapy
• 8.3. Mono Therapy

9. Hypertension Drug Market, by Distribution

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Hypertension Drug Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Hypertension Drug Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Hypertension Drug Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing